Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.
Maurizio Zangari(University of Arkansas for Medical Sciences), Shmuel Yaccoby(Winthrop Rockefeller Foundation), Larry J. Suva(Mitchell Institute), Joshua D. Dilley(University of Arkansas at Little Rock), Guido J. Trico(University of Arkansas at Little Rock), Michael J. Burns(University of Arkansas at Little Rock), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Federica Cavallo, Bart Barlogie(University of Arkansas for Medical Sciences), Dixie Esseltine(Millennium Engineering and Integration (United States)), Mario Boccadoro(University of Turin)
Cited by 7
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k